The pattern of specific endocrine toxicities varies considerably: pituitary inflammation shows predilection for CTLA-4 inhibition (occurring in ∼4% of ipilimumab-treated patients) (17), while thyroid dysfunction predominantly accompanies PD-1 blockade and combination therapy (18). This evidence concerns the gene CTLA4 and inflammation.